Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. Bivona TG, et al. Among authors: taron m. Nature. 2011 Mar 24;471(7339):523-6. doi: 10.1038/nature09870. Nature. 2011. PMID: 21430781 Free PMC article.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Zhang Z, et al. Among authors: taron m. Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330. Nat Genet. 2012. PMID: 22751098 Free PMC article.
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M. Rosell R, et al. Among authors: taron m. Clin Cancer Res. 2011 Mar 1;17(5):1160-8. doi: 10.1158/1078-0432.CCR-10-2158. Epub 2011 Jan 13. Clin Cancer Res. 2011. PMID: 21233402
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. Costa C, et al. Among authors: taron m. Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3. Clin Cancer Res. 2014. PMID: 24493829 Clinical Trial.
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castellà E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Pérez-Cano M, Carrasco E, Tomàs M, Mate JL, Moran T, Rosell R. Molina-Vila MA, et al. Among authors: taron m. J Thorac Oncol. 2008 Nov;3(11):1224-35. doi: 10.1097/JTO.0b013e318189f579. J Thorac Oncol. 2008. PMID: 18978556 Free article.
Biomarkers in lung oncology.
Rosell R, Vergnenegre A, Liu B, Cobo M, Massuti B, Wei J, Molina MA, Costa C, Queralt C, Taron M. Rosell R, et al. Among authors: taron m. Pulm Pharmacol Ther. 2010 Dec;23(6):508-14. doi: 10.1016/j.pupt.2010.05.003. Epub 2010 May 13. Pulm Pharmacol Ther. 2010. PMID: 20471486 Review.
Predictive biomarkers in the management of EGFR mutant lung cancer.
Rosell R, Moran T, Cardenal F, Porta R, Viteri S, Molina MA, Benlloch S, Taron M. Rosell R, et al. Among authors: taron m. Ann N Y Acad Sci. 2010 Oct;1210:45-52. doi: 10.1111/j.1749-6632.2010.05775.x. Ann N Y Acad Sci. 2010. PMID: 20973798
156 results